Published: 15 October 2026 | 6.00 AM
Last Updated: 15 October 2026 | 6.00 AM
Paras Healthcare IPO Review: Price Band, Financials and Chanakya View
IPO Snapshot
| Particulars | Details |
|---|---|
| Chanakya View | 🟡 Cautious; valuation demanding |
| Overall Rating | 2.5/5 |
| GMP Today | Updated daily; unofficial |
| Issue Size | Rs. 1,450 crore |
| Fresh Issue / OFS | Rs. 500 crore / Rs. 950 crore |
| Price Band | Rs. 660–693 |
| Lot Size | 21 shares |
| Minimum Retail Investment | Rs. 14,553 |
| Opens / Closes | 21 / 23 October 2026 |
| Allotment / Listing | 26 / 28 October 2026, tentative |
| Exchanges | BSE, NSE |
| Registrar | MUFG Intime India Pvt. Ltd. |
Investor Decision Box
| Question | Chanakya View |
|---|---|
| Listing Gains? | Depends on demand and pricing |
| Long-Term Investment? | Selective; await earnings consistency |
| Risk Level | High |
| Business Quality | 4/5 |
| Financial Strength | 3/5 |
| Balance Sheet | 2/5 |
👉 | IPO GMP|IPO Reviews |IPO Subscription|IPO Allotment
Chanakya View
Paras Healthcare offers exposure to specialised hospital services through an expanding regional network. Its return to profitability in FY26 and stronger June-quarter earnings strengthen the operating story. However, valuation leaves limited room for disappointment.
At Rs. 693, the pre-issue P/E is approximately 159.7 times FY26 EPS of Rs. 4.34. Allowing for fresh-share dilution, estimated post-issue P/E rises to approximately 171.1 times, assuming unchanged FY26 earnings and issuance at the upper band. These are demanding multiples for a recently profitable, leveraged business.
Debt repayment of Rs. 375 crore could reduce financing pressure, although future expansion will require careful capital management. The June-quarter PAT should not be mechanically annualised: investors need evidence that improved margins are sustainable.
Chanakya Recommendation: 🟡 Consider selectively after evaluating valuation, institutional subscription and sustained profitability. GMP alone cannot establish investment merit.
About the Company
Paras Healthcare operates eight hospitals under the Paras Health brand, with 2,211 beds as of June 2026. Its network spans Gurugram, Panchkula, Patna, Darbhanga, Kanpur, Udaipur, Ranchi and Srinagar.
Cardiac sciences, oncology, neurosciences, gastro sciences, orthopaedics and renal sciences generated 75.30% of FY26 revenue. Planned hospitals in Gurugram and Ludhiana would add 800 beds, taking capacity to 3,011 by March 2028.
Expansion success will depend on doctor retention, patient volumes and operating discipline.
Why This IPO Stands Out
-
Specialised tertiary and quaternary care supports differentiated services.
-
Eight hospitals provide an established operating platform.
-
Planned capacity expansion offers additional growth opportunities.
-
Debt reduction could improve future interest coverage.
Key Risks
-
June borrowings of Rs. 1,429.49 crore remain substantial.
-
FY24 and FY25 losses highlight uneven historical profitability.
-
New hospitals entail execution costs and occupancy ramp-up risk.
-
OFS proceeds go to selling shareholders.
-
Premium pricing increases sensitivity to earnings disappointment.
Financial Snapshot (Rs. Crore)
| Particulars | FY26 | FY25 | FY24 |
|---|---|---|---|
| Total Income | 1,628.78 | 1,314.21 | 1,151.02 |
| EBITDA | 335.58 | 156.46 | 154.41 |
| PAT | 43.83 | -57.98 | -15.33 |
| Net Worth | 394.94 | 280.49 | 338.51 |
| Borrowings | 1,393.86 | 1,232.12 | 923.92 |
Chanakya Interpretation: Income increased 23.94%, while PAT recovered from losses. EBITDA margin reached 20.60%; debt/equity remained elevated at 3.53.
Business Quality Score
| Parameter | Rating |
|---|---|
| Business Model | 4/5 |
| Industry Outlook | 4/5 |
| Financial Performance | 3/5 |
| Management Execution | Monitor |
| Balance Sheet | 2/5 |
| Growth Potential | 4/5 |
Company Address: First Floor, Tower B, Paras Twin Towers, Golf Course Road, Sector 54, Gurugram, Haryana 122002.
Lead Managers: JM Financial, BOFA Securities India and Nuvama Wealth Management.
IPO Proceeds and Why They Matter
| Purpose | Rs. Crore |
|---|---|
| Company debt repayment | 320.90 |
| Subsidiary PMHPL debt repayment | 54.10 |
| General corporate purposes | Balance |
The fresh issue targets financing pressure. Lower interest costs could support profitability, but actual savings will depend on repayment timing and loan terms. The Rs. 950 crore OFS contributes no funds to hospital operations.
Business Outlook
Paras Healthcare’s next phase depends on converting additional beds into profitable patient volumes. Specialised treatments offer growth opportunities, although new hospitals typically need time to establish referral networks and reach efficient occupancy.
Investors should monitor revenue per occupied bed, doctor retention, operating cash flow and capital expenditure. Expansion creates value only when returns justify the investment.
Strengths vs Concerns
| Strengths | Concerns |
|---|---|
| Specialised clinical services | Demanding earnings valuation |
| Regional hospital network | Substantial outstanding debt |
| Additional bed capacity planned | Hospital ramp-up costs |
Who Should Apply?
| Investor Type | Suitability |
|---|---|
| Listing-gain investors | Assess subscription; avoid GMP dependence |
| Patient long-term investors | Selective consideration |
| Conservative investors | Await stronger earnings visibility |
Chanakya Final Verdict
Paras Healthcare combines an established hospital platform with expansion potential and improving earnings. However, its short profitable track record, leverage and demanding valuation reduce the margin of safety. Debt repayment is positive, but sustainable cash generation matters more than one strong quarter. Chanakya’s view remains cautious: consider selectively only after assessing institutional demand and earnings durability. Conservative investors can wait for listed financial results before committing capital.
Frequently Asked Questions
How will Paras Healthcare IPO proceeds be used?
Primarily for debt repayment and general corporate purposes.
What is Paras Healthcare IPO’s minimum investment?
Rs. 14,553 for 21 shares at Rs. 693.
Should investors apply for Paras Healthcare IPO?
Selectively; valuation and leverage warrant caution.
Summary
Paras Healthcare’s growth opportunity requires disciplined execution. Investors should prioritise sustainable profitability, debt reduction and cash flow over grey-market signals.